Autres langues Pulmonx Corporation

Actions

LUNG

US7458481014

Temps réel estimé Cboe BZX Autres places de cotation 17:20:29 02/05/2024			Varia. 5j.	Varia. 1 janv.
9,335 ^USD	+20,92%		+27,12%	-27,22%

01/05	Transcript : Pulmonx Corporation, Q1 2024 Earnings Call, May 01, 2024
01/05	Pulmonx Corporation donne des prévisions de revenus pour l'année 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pulmonx : Investor Presentation – May 2024	12:43
Earnings Flash (LUNG) PULMONX CORPORATION Posts Q1 Revenue $18.9M, vs. Street Est of $17.9M	01/05
Pulmonx Reports First Quarter 2024 Financial Results	01/05
Pulmonx Corporation Provides Revenue Guidance for the Full Year 2024	01/05
Pulmonx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05
Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024	10/04
Pulmonx Appoints Mehul Joshi as Chief Financial Officer	02/04
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer	02/04
Pulmonx Corporation Announces Chief Financial Officer Changes, Effective April 3, 2024	02/04
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	15/03
Pulmonx Announces Treatment of the First Patient with the AeriSeal System in CONVERT II Pivotal Trial	27/02
Pulmonx kondigt behandeling aan van de eerste patiënt met het AeriSeal®-systeem in de CONVERT II-studie	27/02
Pulmonx meldet Behandlung des ersten Patienten mit dem AeriSeal®-System in der CONVERT-II-Zulassungsstudie	27/02
Pulmonx annuncia il trattamento del primo paziente con il sistema AeriSeal® nello studio pivotale CONVERT II	27/02
Pulmonx anuncia el tratamiento del primer paciente con el sistema AeriSeal® en el ensayo pivotal CONVERT II	27/02
Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial	26/02
Pulmonx Corporation Announces Treatment of the First Patient with the Aeriseal System in Convert II Pivotal Trial	26/02
North American Morning Briefing : Traders Await -2-	26/02
Pulmonx Shares Fall After Wells Fargo Downgrade	23/02
Earnings Flash (LUNG) PULMONX CORPORATION Reports Q4 Revenue $19.3M, vs. Street Est of $18.2M	21/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Pulmonx Corporation

Actions

LUNG

US7458481014

Autres langues

Filtres